

## PHARMACY COVERAGE GUIDELINE

### REZUROCK™ (belumosudil) oral Generic Equivalent (if available)

---

#### **This Pharmacy Coverage Guideline (PCG):**

- Provides information about the reasons, basis, and information sources we use for coverage decisions
- Is not an opinion that a drug (collectively “Service”) is clinically appropriate or inappropriate for a patient
- Is not a substitute for a provider’s judgment (Provider and patient are responsible for all decisions about appropriateness of care)
- Is subject to all provisions e.g. (benefit coverage, limits, and exclusions) in the member’s benefit plan; and
- Is subject to change as new information becomes available.

#### **Scope**

- This PCG applies to Commercial and/or Marketplace plans
- This PCG does not apply to the Federal Employee Program, Medicare Advantage, Medicaid or members of out-of-state Blue Cross and/or Blue Shield Plans

#### **Instructions & Guidance**

- To determine whether a member is eligible for the Service, read the entire PCG.
- This PCG is used for FDA approved indications including, but not limited to, a diagnosis and/or treatment with dosing, frequency, and duration.
- Use of a drug outside the FDA approved guidelines, refer to the appropriate Off-Label Use policy.
- The “Criteria” section outlines the factors and information we use to decide if the Service is medically necessary as defined in the Member’s benefit plan.
- The “Description” section describes the Service.
- The “Definition” section defines certain words, terms or items within the policy and may include tables and charts.
- The “Resources” section lists the information and materials we considered in developing this PCG
- **We do not accept patient use of samples as evidence of an initial course of treatment, justification for continuation of therapy, or evidence of adequate trial and failure.**
- Information about medications that require prior authorization is available at [www.azblue.com/pharmacy](http://www.azblue.com/pharmacy). You must fully complete the [request form](#) and provide chart notes, lab workup and any other supporting documentation. The prescribing provider must sign the form. Fax the form to BCBSAZ Pharmacy Management at (602) 864-3126 or email it to [Pharmacyprecert@azblue.com](mailto:Pharmacyprecert@azblue.com).

---

## Medical Necessity Requirements for REZUROCK (belumosudil)

---

### Criteria for Initial Therapy:

#### **Prescriber Qualifications**

- Prescribed by a physician specializing in the diagnosis or in consultation with a transplant specialist

#### **Indication**

- Chronic graft versus host disease (cGVHD) after failure of at least two prior lines of systemic therapy (e.g., mycophenolate, tacrolimus, cyclosporine, sirolimus, ruxolitinib, ibrutinib, imatinib, methylprednisolone, etc.)

## PHARMACY COVERAGE GUIDELINE

### REZUROCK™ (belumosudil) oral Generic Equivalent (if available)

---

- Other oncologic direct treatment use listed in National Comprehensive Cancer Network (National Comprehensive Cancer Network) Guidelines with Categories of Evidence and Consensus of 1 and 2A

#### Age Requirement

- 12 years or older and weighing at least 40 kilograms

#### Baseline Clinical Evaluation

- Evidence of persistent chronic graft versus host disease manifestations
- History of allogeneic hematopoietic cell transplant
- Receiving stable dose of glucocorticoid therapy
- Negative pregnancy test (if applicable)
- **ONE** of the following performance scores:
  - For age 16 years or older: Karnofsky Performance Score of greater than or equal to 60
  - For age between 12 and less than 16 years: Lansky Performance Score of greater than or equal to 60

#### Brand Specific Criteria

- Have failure, contraindication or intolerance with **THREE** generic equivalents (when available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the U.S. Food and Drug Administration (see Definitions section)

#### Safety

- Does not have moderate to severe hepatic impairment (Child Pugh Class B or C) without liver graft versus host disease

#### Documentation Requirements

- A completed request form must be submitted, including:
  - Chart notes
  - Lab results (e.g., performance scores, pregnancy test)
  - Supporting clinical documentation

#### Initial Therapy Criteria Approval Duration:

- 6 months OR end of plan year
- 

### Criteria for Continuation of Therapy (renewal therapy):

**Note: Manufacturer assistance (e.g., coupons, samples, etc.) are not considered for continuation of therapy**

#### Prescriber Qualifications

- Continues to be seen by a physician specializing in or is in consultation with a transplant specialist

#### Clinical Response

- Positive clinical response defined as **TWO** of the following:

ORIGINAL EFFECTIVE DATE: 08/19/1921 | ARCHIVE DATE: | LAST REVIEW DATE: 08/21/2025 | LAST CRITERIA REVISION DATE: 08/15/2024

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

## PHARMACY COVERAGE GUIDELINE

### REZUROCK™ (belumosudil) oral Generic Equivalent (if available)

---

- No evidence of disease progression
- No significant unacceptable adverse drug reactions
- Achieved and maintains at least a 7 point reduction in Lee Chronic Graft versus Host Symptom Scale Score over baseline

#### Brand Specific Criteria

- Have failure, contraindication or intolerance with **THREE** generic equivalents (when available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the FDA (see Definitions section)

#### Adherence

- Adherence to the prescribed therapy regimen has been documented

#### Safety

- No development of hepatotoxicity or other life threatening adverse effects
- Does not have moderate to severe hepatic impairment (Child Pugh Class B or C) without liver graft versus host disease

#### Documentation Requirements

- Chart notes
- Supporting clinical documentation with evidence of improvement in given indication
- Lab values that confirm safe use from above criteria

#### Continuation Therapy Criteria Approval Duration:

- 12 months OR end of plan year
- 

### Criteria for Off-Label Use Requests:

Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:

1. Off-Label Use of Non-Cancer Medications
  2. Off-Label Use of Cancer Medications
- 

#### Description:

Rezurock (belumosudil) is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.

## PHARMACY COVERAGE GUIDELINE

### REZUROCK™ (belumosudil) oral Generic Equivalent (if available)

Belumosudil is an inhibitor of rho-associated, coiled-coil containing protein kinase (ROCK) which inhibits ROCK1 and ROCK2. Belumosudil down-regulates proinflammatory responses via regulation of signal transducer and activator transcription (STAT) 3 and STAT 5 phosphorylation and shifting Th17/Treg balance in *ex-vivo* or *in vitro* human T cell assays. Belumosudil also inhibited aberrant pro-fibrotic signaling, *in vitro*. *In vivo*, belumosudil demonstrated activity in animal models of chronic GVHD.

#### Definitions:

U.S. Food and Drug Administration (FDA) MedWatch Forms for FDA Safety Reporting  
[MedWatch Forms for FDA Safety Reporting | FDA](#)

Clinical manifestations of chronic GVHD include:

- Skin involvement (e.g., resembling lichen planus or cutaneous manifestations of scleroderma)
- Dry oral mucosa with ulcerations and sclerosis
- Gastrointestinal tract effects (e.g., exudates, erosions, ulceration)
- Lungs (e.g., bronchiolitis obliterans diagnosed by biopsy)

Acute GVHD commonly includes presence of a classic maculopapular rash; abdominal cramps with diarrhea; and arising serum bilirubin concentration

#### Karnofsky Performance Scale:

Score	Description	
100	Normal, no complaints, no evidence of disease	Able to carry on normal activity and to work
90	Able to carry on normal activity, only minor signs or symptoms of disease present	
80	Normal activity with effort, some signs or symptoms of disease present	No special care needed
70	Cares for self, but unable to carry on normal activity or do active work	Unable to work but able to live at home and care for most personal needs
60	Requires occasional assistance from others, but is able to care for most of his/her needs	
50	Requires considerable assistance from others and needs frequent medical care	Various degrees of assistance may be needed
40	Disabled, requires special care and assistance	
30	Severely disabled, hospitalization indicated, but death not imminent	Unable to care for self
20	Very sick, hospitalization indicated, active support treatment is necessary but death not imminent	
10	Moribund, fatal process progressing rapidly	
0	Dead	

#### Lansky Performance Scale:

Score	Description
100	Fully active, normal
90	Minor restrictions in physical strenuous activity
80	Active, but tires more quickly
70	Both greater restriction of, and less time spent in, play activity
60	Up and around, but minimal active play; keeps busy with quieter activities

ORIGINAL EFFECTIVE DATE: 08/19/1921 | ARCHIVE DATE: | LAST REVIEW DATE: 08/21/2025 | LAST CRITERIA REVISION DATE: 08/15/2024

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

**PHARMACY COVERAGE GUIDELINE**

**REZUROCK™ (belumosudil) oral  
Generic Equivalent (if available)**

50	Gets dressed, but lies around much of the day; no active play; able to participate in all quiet play and activities
40	Mostly in bed, participates in quiet activities
30	In bed, needs assistance even for quiet play
20	Often sleeping, play entirely limited to very passive activities
10	No play, does not get out of bed
0	Dead

**Lee Chronic Graft-versus-Host Symptom Scale:**

Lee chronic graft versus host symptom scale	
Have you been bothered by any of the following problems in the last month	0 = not at all 1 = slightly 2 = moderately 3 = quite a bit 4 = extremely
<b>Skin:</b>	
a. Abnormal skin color	0 1 2 3 4
b. Rashes	0 1 2 3 4
c. Thickened skin	0 1 2 3 4
d. Sores on skin	0 1 2 3 4
e. Itchy skin	0 1 2 3 4
<b>Eyes and mouth:</b>	
f. Dry eyes	0 1 2 3 4
g. Need to use eyedrops frequently	0 1 2 3 4
h. Difficulty seeing clearly	0 1 2 3 4
i. Need to avoid certain foods due to mouth pain	0 1 2 3 4
j. Ulcers in mouth	0 1 2 3 4
k. Receiving nutrition from an intravenous line or feeding tube	0 1 2 3 4
<b>Breathing:</b>	
l. Frequent cough	0 1 2 3 4
m. Colored sputum	0 1 2 3 4
n. Shortness of breath with exercise	0 1 2 3 4
o. Shortness of breath at rest	0 1 2 3 4
p. Need to use oxygen	0 1 2 3 4
<b>Eating and digestion:</b>	
q. Difficulty swallowing solid foods	0 1 2 3 4
r. Difficulty swallowing liquids	0 1 2 3 4
s. Vomiting	0 1 2 3 4
t. Weight loss	0 1 2 3 4
<b>Muscles and joints:</b>	
u. Joint and muscle aches	0 1 2 3 4
v. Limited joint movement	0 1 2 3 4
w. Muscle cramps	0 1 2 3 4
x. Weak muscles	0 1 2 3 4

ORIGINAL EFFECTIVE DATE: 08/19/1921 | ARCHIVE DATE: | LAST REVIEW DATE: 08/21/2025 | LAST CRITERIA REVISION DATE: 08/15/2024

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

## PHARMACY COVERAGE GUIDELINE

### REZUROCK™ (belumosudil) oral Generic Equivalent (if available)

<b>Energy:</b>					
y. Loss of energy	0	1	2	3	4
z. Need to sleep more/take naps	0	1	2	3	4
aa. Fevers	0	1	2	3	4
<b>Mental health and emotional:</b>					
bb. Depression	0	1	2	3	4
cc. Anxiety	0	1	2	3	4
dd. Difficulty sleeping	0	1	2	3	4

### Resources:

Rezurock (belumosudil) product information, revised by Kadmon Pharmaceuticals, LLC. 04-2024. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed May 13, 2025.

Zeiser R. Clinical manifestations and diagnosis chronic graft-versus-host disease. In: UpToDate, Negrin RS, Chao NJ, Rosmarin AG (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through May 2025.. Topic last updated February 27, 2024. Accessed June 24, 2025

Zeiser R. Treatment of chronic graft-versus-host disease. In: UpToDate, Negrin RS, Chao NJ, Rosmarin AG (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through May 2025. Topic last updated September 25, 2024. Accessed June 24, 2025.

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Hematopoietic Cell Transplantation Version 2.2025– Updated June 03, 2025 Available at <https://www.nccn.org>. Accessed June 24, 2025.

Cutler C, Lee SJ, Arai S, et al.: Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood 2021 Dec 2; 138(22): 2278–2289. Accessed July 16, 2024.

[ClinicalTrials.gov](http://clinicaltrials.gov) [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03640481. A Phase 2, Randomized Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Therapy (The ROCKstar Study). Last Update Posted Aug 03, 2021. Available from: <http://clinicaltrials.gov>. Accessed August 08, 2021. Re-reviewed on July 16, 2024.

Lee SJ, Cook EF, Soiffer R, Antin JH.: Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation 2002; 8:444-452. Accessed August 09, 2021. Re-reviewed on July 16, 2024.

Off Label Use of Cancer Medications: A.R.S. §§ 20-826(R) & (S). Subscription contracts; definitions.

Off Label Use of Cancer Medications: A.R.S. §§ 20-1057(V) & (W). Evidence of coverage by health care service organizations; renewability; definitions.